Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 22, 2023
Finance
March 22 Quick Takes: GordonMD, Pfizer Ventures lead Flare’s $123M B round
Plus: FDA approvals for Cidara, Incyte and updates from Karuna, Astellas, NImmune, AbbVie, Roche, Lilly
BioCentury | Dec 10, 2019
Finance
Perceptive launches $210M early-stage fund tied to Garabedian’s accelerator Xontogeny
Perceptive’s first early-stage fund will invest in fledgling companies progressing toward proof of concept
BioCentury | Apr 20, 2018
Emerging Company Profile
Clear for Landos
How Landos’ first-in-class LANCL2 agonist could improve upon existing IBD drugs
Items per page:
1 - 7 of 7